Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (5): 699-704    DOI: 10.31083/j.ejgo.2020.05.5447
Original Research Previous articles | Next articles
SIRT1 is overexpressed in endometrial adenocarcinoma: a tissue microarray analysis
Jaudah Al-Maghrabi1, 2, *(), Haneen Al-Maghrabi2
1Department of Pathology, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia
2Department of Pathology, King Faisal Specialist Hospital and Research centre, Jeddah 21499, Saudi Arabia
Download:  PDF(2579KB)  ( 215 ) Full text   ( 10 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Silent mating type information regulation 2 homolog-1 (SIRT1) is a member of sirtuin family. Its role in endometrial carcinoma (EC) is controversial and unclear. This study aims to define the SIRT1 immunoexpression pattern in endometrial carcinoma (EC), its relationship with clinicopathological features, and its prognostic significance. A tissue microarray was constructed and contained 71 endometrial carcinomas, 28 endometrial hyperplasia, and 30 normal endometrial tissues. An immunostaining study was completed using anti-SIRT rabbit polyclonal antibody. SIRT1 immunoexpression was scored and analysed. Positive immunostaining was found in 29 of the 71 (40.8%) endometrial carcinomas and in 7 of the 58 (12.1%) nonneoplastic endometrial tissues. SIRT1 immunoexpression findings were not related to age, histological type, tumor size, myometrial invasion, lymphovascular invasion, surgical resection margin, lymph node metastasis, FIGO staging, local recurrence or survival. In endometrial carcinoma, SIRT1 immunoexpression is expressed at greater levels in malignant endometrial tissue than in hyperplastic and normal endometrial tissues. However, no relationship was found between SIRT1 expression and other clinicopathological parameters. More studies are needed to explore the role of SIRT1 in ECs.
Key words:  Endometrium      Tissue Microarray      Immunohistochemistry      SIRT1     
Submitted:  11 October 2019      Accepted:  24 March 2020      Published:  15 October 2020     
*Corresponding Author(s):  JAUDAH AL-MAGHRABİ     E-mail:  jalmaghrabi@hotmail.com

Cite this article: 

Jaudah Al-Maghrabi, Haneen Al-Maghrabi. SIRT1 is overexpressed in endometrial adenocarcinoma: a tissue microarray analysis. European Journal of Gynaecological Oncology, 2020, 41(5): 699-704.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.05.5447     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I5/699

[1] Wook Youn Kim, Shin Hee Seo, Seung-Hyuk Shim, Jin Hee Park, Hyung Kyu Park, Kyeong A So, Tae Jin Kim, Sun Joo Lee. Correlation of immunohistochemistry and silver in situ hybridization for the assessment of c-MET in uterine cervical cancer patients treated with radical hysterectomy[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 745-752.
[2] Hyang Sook Jeong, Yuki Gen, Hui Ryun Joo, Ji Geun Yoo, Seung Geun Yeo, Dong Choon Park. Mesonephric-like carcinoma of the uterine corpus: A case report and literature review[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 664-667.
[3] Soo-Young Lee, Dae-Hyung Lee. Perivascular epithelioid cell tumor arising in the left parametrium: a case report[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 657-660.
[4] Marcin Jedryka, Agnieszka Chrobak, Anna Chelmonska-Soyta, Daria Fijalkowska, Rafal Matkowski. Decreased expression of estrogen receptors alpha and beta in peripheral blood lymphocytes from the endometrial cancer patients and women with endometriosis[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 375-379.
[5] H. Cokmez, A. Yilmaz. Concordance of preoperative and postoperative histological grades in endometrioid type endometrial cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 208-213.
[6] Sung-Im Do, Hee-Chul Shin, Hee Sung Kim. Clinical significance of MET receptor protein and mRNA expression in invasive breast cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 240-245.
[7] Y. S. Lee, J. M. Baek, E. K. Park, C. J. Kim, H. J. Lee, J. O. Kim. Expression and therapeutic potential of macrophage migration inhibitory factor and CD74 in ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 65-69.
[8] M.H. Hajeer, A. Al Khader, N.A. Shahin, M.S. Bata. Negative p53 expression and negative high risk HPV in a 26-year-old lady with vulvar keratinizing squamous cell carcinoma: report of a case[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 130-133.
[9] R. Tasaka, Y. Hashiguchi, M. Kasai, T. Fukuda, T. Ichimura, T. Yasui, T. Sumi. Secondary small cell carcinoma of the endometrium after concurrent chemoradiotherapy for cervical cancer: a rare case[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 142-144.
[10] N. K. Šuster, M. Meznaric, N. Škorja, I. Virant-Klun, I. Verdenik, Š. Smrkolj. Cancer stem cell-related marker NANOG expression in ovarian serous tumors using Western blotting and immunohistochemistry: comparison of two techniques[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 948-952.
[11] Yangyang Shi, Yongyun Shi, Dabao Wu. A case of placental site trophoblastic tumor and a retrospective analysis[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1096-1099.
[12] H. Ibrahim, K. Dresser, K. M. Cornejo. Loss of 5-hydroxymethylcytosine (5-hmC) expression in endometrioid type endometrial carcinoma[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 846-848.
[13] A.M. Sindiani, M.S. Alorjani, B.K. Aldaraiseh. Dysgerminoma of the ovary in an adolescent girl associated with a high serum β-human chorionic gonadotropin (β-hCG) level[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 859-861.
[14] S. Kabukcuoglu, B. Hayit. Histopathologic features of advanced stage endometrial carcinoma[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 614-618.
[15] X. Lyu, P. Liu, H. Mao, B. Han, X. Wei. Small cell carcinoma of the endometrium mixed with endometriod adenocarcinoma: a case report[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 676-678.
[1] Eli M. Roth, Michael H. Davidson. PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 31 -46 .
[2] B. Soltész, J. Lukács, A. Penyige, R. Póka, B. Nagy. Determination of miR-193b rs30236 single nucleotide polymorphism in ovarian cancer patients[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 547 -550 .
[3] Y. Li, C. Li, N. Li, L. Jiang, W. Yang, Y. Wang, B. Wu, C. Shi, Z. Zhu. RNAi silenced NUP88 gene suppresses growth and invasiveness of human breast cancer cell line MCF-7[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 634 -639 .
[4] M. Pakiž, L. Lukman, N. Kozar. Patients' and physicians' expectations differ significantly during the follow-up period after completion of primary treatment of gynecological or breast cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 781 -786 .
[5] T. Tomimatsu, S. Mabuchi, T. Tsuboyama, Y. Hori, S. Sekine, T. Kimura. Malignant transformation of uterine leiomyoma: suggested by clinical, imaging, histological, and genetic findings[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 879 -882 .
[6] Z. Protrka, P. Arsenijevic, N. Jovic, S. Zivanovic, J. Djuric, A. Dimitrijevic. A case of uterine torsion in term pregnancy associated with placental abruption and intrauterine fetal demise[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(2): 287 -289 .
[7] T. Ueno, H. Yabushita, K. Iwasaki, A. Wakatsuki. Role of adiponectin and leptin in non-diabetic, non-obese patients with endometrial cancer[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 199 -204 .
[8] P. Pimsi, W. Santimaleeworagun, S. Therasakvichya, N. Saengsukkasemsak, A. Laocharoenkeat. The incidence and risk factors of severe neutropenia and febrile neutropenia due to chemotherapy among gynecologic cancer patients in Thailand[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 242 -246 .
[9] F. Lai-Tiong. Dermatomyositis revealing a 18-year breast cancer recurrence[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 292 -293 .
[10] M.F. Benoit, K.A. O'Hanlan, M.S. Sten, C.L. Kosnik, D.M. Struck, M.S. O'Holleran, J. Cuff, D.M. Halliday, E.A. Kent. Incidental appendectomy at the time of gynecologic surgery[J]. European Journal of Gynaecological Oncology, 2018, 39(3): 386 -389 .